Impact Of Eplerenone On Cardiovascular Outcomes In Patients Post Myocardial Infarction
Status:
Completed
Trial end date:
2012-10-01
Target enrollment:
Participant gender:
Summary
Administration of eplerenone within 24 hours of onset of symptoms of myocardial infarction,
in patients without heart failure, reduces cardiovascular mortality / morbidity.
Phase:
Phase 4
Details
Lead Sponsor:
Pfizer Pfizer's Upjohn has merged with Mylan to form Viatris Inc.